Bright Peak Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of BPT567, a First-in-Class Bifunctional PD1-IL18 Immunoconjugate
– BPT567 is the first bifunctional PD1-IL18 immunoconjugate to enter clinical development – – Phase 1/2a study will evaluate BPT567 in patients with locally advanced/unresectable or metastatic solid tumors – BASEL, Switzerland and SAN DIEGO, Oct. 17, 2024 (Korea Bizwire) – Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies [...]